ANAB Straddle Strategy
ANAB (AnaptysBio, Inc.), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor (IL-36R) for the treatment of various dermatological inflammatory diseases; Rosnilimab, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through rosnilimab treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
ANAB (AnaptysBio, Inc.) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $2.70B, a beta of 0.48 versus the broader market, a 52-week range of 11.404-72.36, average daily share volume of 838K, a public-listing history dating back to 2017, approximately 136 full-time employees. These structural characteristics shape how ANAB stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 0.48 indicates ANAB has historically moved less than the broader market, dampening realized volatility and producing tighter expected-move bands per unit of dollar exposure.
What is a straddle on ANAB?
A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration.
Current ANAB snapshot
As of May 15, 2026, spot at $63.21, ATM IV 77.80%, IV rank 22.37%, expected move 22.30%. The straddle on ANAB below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this straddle structure on ANAB specifically: ANAB IV at 77.80% is on the cheap side of its 1-year range, which favors premium-buying structures like a ANAB straddle, with a market-implied 1-standard-deviation move of approximately 22.30% (roughly $14.10 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated ANAB expiries trade a higher absolute premium for lower per-day decay. Position sizing on ANAB should anchor to the underlying notional of $63.21 per share and to the trader's directional view on ANAB stock.
ANAB straddle setup
The ANAB straddle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With ANAB near $63.21, the first option leg uses a $63.21 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed ANAB chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 ANAB shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $63.21 | N/A |
| Buy 1 | Put | $63.21 | N/A |
ANAB straddle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit.
ANAB straddle payoff curve
Modeled P&L at expiration across a range of underlying prices for the straddle on ANAB. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use straddle on ANAB
Straddles on ANAB are pure-volatility plays that profit from large moves in either direction; traders typically buy ANAB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
ANAB thesis for this straddle
The market-implied 1-standard-deviation range for ANAB extends from approximately $49.11 on the downside to $77.31 on the upside. A ANAB long straddle is a pure-volatility play: it profits when the underlying moves far enough from the strike in either direction to overcome the combined call plus put debit, regardless of direction. Current ANAB IV rank near 22.37% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on ANAB at 77.80%. As a Healthcare name, ANAB options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to ANAB-specific events.
ANAB straddle positions are structurally neutral / high-volatility (long premium); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. ANAB positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move ANAB alongside the broader basket even when ANAB-specific fundamentals are unchanged. Always rebuild the position from current ANAB chain quotes before placing a trade.
Frequently asked questions
- What is a straddle on ANAB?
- A straddle on ANAB is the straddle strategy applied to ANAB (stock). The strategy is structurally neutral / high-volatility (long premium): A long straddle buys an ATM call and an ATM put at the same strike, profiting from a large move in either direction; max loss equals the combined debit when the underlying pins to the strike at expiration. With ANAB stock trading near $63.21, the strikes shown on this page are snapped to the nearest listed ANAB chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are ANAB straddle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the strike minus the combined call plus put debit (reached at zero). Max loss equals the combined debit times 100 (reached when the underlying pins to the strike). Two breakevens at strike plus debit and strike minus debit. For the ANAB straddle priced from the end-of-day chain at a 30-day expiry (ATM IV 77.80%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a ANAB straddle?
- The breakeven for the ANAB straddle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current ANAB market-implied 1-standard-deviation expected move is approximately 22.30%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a straddle on ANAB?
- Straddles on ANAB are pure-volatility plays that profit from large moves in either direction; traders typically buy ANAB straddles ahead of earnings, FDA decisions, or other catalysts where the realized move is expected to exceed the implied move priced into the chain.
- How does current ANAB implied volatility affect this straddle?
- ANAB ATM IV is at 77.80% with IV rank near 22.37%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.